**Question:** An antiemetic drug that also decreases acid secretion due to its action on H1 receptors is

A. Ondansetron
B. Metoclopramide
C. Dexamethasone
D. Ranitidine

**Correct Answer:** D. Ranitidine

**Core Concept:**
H1 receptors are a subtype of histamine receptors, which play a role in modulating various physiological processes, including gastric acid secretion. Histamine is a chemical messenger that stimulates the release of gastric acid from parietal cells in the stomach, leading to increased acid production. H1 receptors are primarily involved in mediating the vasoconstrictor and antihistamine effects.

**Why the Correct Answer is Right:**
Ranitidine is a histamine H2-receptor antagonist, which works by blocking the binding of histamine to H2 receptors on the parietal cells in the stomach. By inhibiting the release of gastric acid, ranitidine effectively reduces acid production. As an added benefit, ranitidine also acts on H1 receptors, which contributes to its antiemetic effect. Therefore, ranitidine is an effective antiemetic and anti-secretory drug due to its action on both H1 and H2 receptors.

**Why Each Wrong Option is Incorrect:**

A. Ondansetron: Ondansetron is a selective 5-HT3 receptor antagonist, which primarily targets the emetic pathway. It does not directly affect gastric acid secretion or H1 receptors, making it less effective in reducing acid production compared to ranitidine.

B. Metoclopramide: Metoclopramide is a dopamine D2 receptor agonist that indirectly enhances acetylcholine release and reduces gastric تفريغ, leading to decreased gastric acid secretion. However, like ondansetron, metoclopramide primarily targets the emetic pathway and does not directly affect H1 receptors.

C. Dexamethasone: Dexamethasone is a synthetic corticosteroid with anti-inflammatory, immunosuppressive, and antiemetic effects. While it does reduce gastric acid secretion, this effect is secondary to its anti-inflammatory action on the gastric mucosa. Dexamethasone does not specifically target H1 receptors, making it less effective than ranitidine for reducing acid production.

**Clinical Pearl:**
Ranitidine's effectiveness in reducing gastric acid production and its action on H1 receptors make it a more comprehensive choice compared to the other options for reducing nausea and vomiting induced by chemotherapy or surgery, as well as gastrointestinal ulcers, gastritis, and peptic ulcer disease.